Hosted on MSN1mon
Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025
EVP Marion McCourt responded that EYLEA HD's profile, including durability and potential label enhancements, strengthens its competitive position. Tyler Van Buren, TD Cowen: Asked about the timing ...
pharmaphorum10y
Eylea beats rivals in government-sponsored head-to-head trial
The trial was sponsored by the US government ... and compared Eylea versus Novartis' rival treatment Lucentis, and Roche's Avastin. The trial came about because of extensive off-label prescribing ...
pharmaphorum5y
Novartis backs brolucizumab with new head-to-head Eylea trial
The wild card in the wet AMD market is off-label use of Roche’s VEGF ... Meanwhile, patents on both Lucentis and Eylea are due to expire in the US in 2020, raising the prospect of additional ...
Seeking Alpha13d
Regeneron falls after appeals court ruling in Eylea case (update)
Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed by an appeals court.
Nasdaq1mon
Regeneron Reports Positive Three-Year Results for EYLEA HD Treatment in Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept ... genetic medicine platforms, enabling us to identify innovative targets and ...